prednisolone has been researched along with Atresia, Biliary in 25 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Stool color (SC) for monitoring prednisolone use in biliary atresia (BA) patients after laparoscopic portoenterostomy (LPE) was reviewed." | 8.31 | Prednisolone administration monitored by postoperative stool color achieves high jaundice clearance after laparoscopic portoenterostomy for biliary atresia. ( Cazares, J; Koga, H; Lane, GJ; Ochi, T; Shibuya, S; Takeda, M; Tsuboi, K; Tsukui, T; Yamataka, A, 2023) |
| "Prednisolone is used routinely after portoenterostomy (PE) in patients with biliary atresia (BA)." | 7.73 | Optimum prednisolone usage in patients with biliary atresia postportoenterostomy. ( Kobayashi, H; Koga, H; Lane, GJ; Miyano, T; Okazaki, T; Tamura, T; Urao, M; Yamataka, A; Yanai, T, 2005) |
| "The underlying diagnoses were biliary atresia (n = 17), acute liver failure (n = 4), metabolic disease (n = 4)." | 5.32 | C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ( Broering, DC; Burdelski, M; Ganschow, R; Grabhorn, E; Hinrichs, B; Mir, TS; Richter, A; Rogiers, X; Schulz, A; von Hugo, A, 2004) |
| "The literature was searched using the following terms: biliary atresia, portoenterostomy, steroids, glucocorticoids, dexamethasone, prednisolone, and hydrocortisone." | 4.90 | Postoperative steroids after Kasai portoenterostomy for biliary atresia: a meta-analysis. ( Jia, J; Wang, JX; Yang, HY; Yue, M; Zhang, D; Zhao, G, 2014) |
| "Stool color (SC) for monitoring prednisolone use in biliary atresia (BA) patients after laparoscopic portoenterostomy (LPE) was reviewed." | 4.31 | Prednisolone administration monitored by postoperative stool color achieves high jaundice clearance after laparoscopic portoenterostomy for biliary atresia. ( Cazares, J; Koga, H; Lane, GJ; Ochi, T; Shibuya, S; Takeda, M; Tsuboi, K; Tsukui, T; Yamataka, A, 2023) |
| "Prednisolone is used routinely after portoenterostomy (PE) in patients with biliary atresia (BA)." | 3.73 | Optimum prednisolone usage in patients with biliary atresia postportoenterostomy. ( Kobayashi, H; Koga, H; Lane, GJ; Miyano, T; Okazaki, T; Tamura, T; Urao, M; Yamataka, A; Yanai, T, 2005) |
| "Biliary atresia is the most common cause of end-stage liver disease in children." | 2.79 | Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial. ( Bezerra, JA; Erlichman, J; Haber, B; Hertel, PM; Karpen, SJ; Kerkar, N; Loomes, KM; Magee, JC; Molleston, JP; Moore, J; Murray, KF; Robuck, PR; Romero, R; Rosenthal, P; Schwarz, KB; Shepherd, R; Sherker, AH; Shneider, BL; Sokol, RJ; Spino, C; Suchy, FJ; Turmelle, YP; Wang, KS; Whitington, PF, 2014) |
| "The association of biliary atresia (BA) and idiopathic thrombocytopenic purpura (ITP) is extremely rare, with only 2 cases being reported in the literature." | 2.45 | Idiopathic thrombocytopenic purpura complicated with biliary atresia: a rare occurrence and literature review. ( Hashimoto, S; Honda, S; Kaneta, M; Kobayashi, R; Okada, T; Sasaki, F; Todo, S, 2009) |
| "The original disease was biliary atresia in all recipients." | 1.56 | Pregnancy Outcomes Following Pediatric Liver Transplantation: A Single-Center Experience in Japan. ( Hirata, Y; Katano, T; Miyahara, G; Naya, I; Okada, N; Onishi, Y; Sakuma, Y; Sanada, Y; Sata, N; Yamada, N, 2020) |
| "Other postoperative complications were noted in eight, but with no fatal cases." | 1.36 | Evaluating patients' outcome post-Kasai operation: a 19-year experience with modification of the hepatic portoenterostomy and applying a novel steroid therapy regimen. ( Hashimoto, T; Hussein, MH; Kondo, S; Sato, Y; Suzuki, T, 2010) |
| " Intravenous prednisolone dosage was started with 4 mg/kg per day and tapered by a half dose every 2 days." | 1.33 | Glucocorticoid receptor alpha expression in the intrahepatic biliary epithelium and adjuvant steroid therapy in infants with biliary atresia. ( Muraji, T; Tatekawa, Y; Tsugawa, C, 2005) |
| "The underlying diagnoses were biliary atresia (n = 17), acute liver failure (n = 4), metabolic disease (n = 4)." | 1.32 | C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ( Broering, DC; Burdelski, M; Ganschow, R; Grabhorn, E; Hinrichs, B; Mir, TS; Richter, A; Rogiers, X; Schulz, A; von Hugo, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeda, M | 1 |
| Tsukui, T | 1 |
| Cazares, J | 1 |
| Tsuboi, K | 1 |
| Ochi, T | 1 |
| Shibuya, S | 1 |
| Koga, H | 3 |
| Lane, GJ | 3 |
| Yamataka, A | 3 |
| Tanaka, Y | 1 |
| Shirota, C | 1 |
| Tainaka, T | 1 |
| Sumida, W | 1 |
| Oshima, K | 1 |
| Makita, S | 1 |
| Tanaka, T | 1 |
| Tani, Y | 1 |
| Chiba, K | 1 |
| Uchida, H | 1 |
| Naya, I | 1 |
| Sanada, Y | 1 |
| Katano, T | 1 |
| Miyahara, G | 1 |
| Hirata, Y | 1 |
| Yamada, N | 1 |
| Okada, N | 1 |
| Onishi, Y | 1 |
| Sakuma, Y | 1 |
| Sata, N | 1 |
| Yeh, YT | 1 |
| Lin, NC | 1 |
| Yeh, YC | 1 |
| Tsai, HL | 1 |
| Chen, CY | 1 |
| Liu, CP | 1 |
| Liu, C | 1 |
| Davenport, M | 3 |
| Parsons, C | 1 |
| Tizzard, S | 1 |
| Hadzic, N | 2 |
| Nio, M | 1 |
| Muraji, T | 3 |
| Bezerra, JA | 1 |
| Spino, C | 1 |
| Magee, JC | 1 |
| Shneider, BL | 1 |
| Rosenthal, P | 1 |
| Wang, KS | 1 |
| Erlichman, J | 1 |
| Haber, B | 1 |
| Hertel, PM | 1 |
| Karpen, SJ | 1 |
| Kerkar, N | 1 |
| Loomes, KM | 1 |
| Molleston, JP | 1 |
| Murray, KF | 1 |
| Romero, R | 1 |
| Schwarz, KB | 1 |
| Shepherd, R | 1 |
| Suchy, FJ | 1 |
| Turmelle, YP | 1 |
| Whitington, PF | 1 |
| Moore, J | 1 |
| Sherker, AH | 1 |
| Robuck, PR | 1 |
| Sokol, RJ | 1 |
| Zhang, D | 1 |
| Yang, HY | 1 |
| Jia, J | 1 |
| Zhao, G | 1 |
| Yue, M | 1 |
| Wang, JX | 1 |
| Chen, Y | 1 |
| Nah, SA | 1 |
| Chiang, L | 1 |
| Krishnaswamy, G | 1 |
| Low, Y | 1 |
| Tyraskis, A | 1 |
| Chung, HY | 1 |
| Kak Yuen Wong, K | 1 |
| Cheun Leung Lan, L | 1 |
| Kwong Hang Tam, P | 1 |
| Okada, T | 1 |
| Sasaki, F | 1 |
| Honda, S | 1 |
| Hashimoto, S | 1 |
| Kobayashi, R | 1 |
| Kaneta, M | 1 |
| Todo, S | 1 |
| Andrade, Wde C | 1 |
| Tannuri, U | 1 |
| da Silva, LF | 1 |
| Alves, VA | 1 |
| Suzuki, T | 1 |
| Hashimoto, T | 1 |
| Kondo, S | 1 |
| Sato, Y | 1 |
| Hussein, MH | 1 |
| Arii, R | 1 |
| Arakawa, A | 1 |
| Miyahara, K | 1 |
| Okazaki, T | 2 |
| Urao, M | 2 |
| Grabhorn, E | 2 |
| Ganschow, R | 2 |
| Helmke, K | 1 |
| Rogiers, X | 2 |
| Burdelski, M | 2 |
| Richter, A | 1 |
| Schulz, A | 1 |
| von Hugo, A | 1 |
| Mir, TS | 1 |
| Broering, DC | 1 |
| Hinrichs, B | 1 |
| Kobayashi, H | 1 |
| Tamura, T | 1 |
| Yanai, T | 1 |
| Miyano, T | 1 |
| Tatekawa, Y | 1 |
| Tsugawa, C | 1 |
| Wei, SH | 1 |
| Ho, MC | 1 |
| Ni, YH | 1 |
| Lin, DT | 1 |
| Lee, PH | 1 |
| Shimadera, S | 1 |
| Iwai, N | 1 |
| Deguchi, E | 1 |
| Kimura, O | 1 |
| Fumino, S | 1 |
| Ono, S | 1 |
| Stringer, MD | 1 |
| Tizzard, SA | 1 |
| McClean, P | 1 |
| Mieli-Vergani, G | 1 |
| Vejchapipat, P | 1 |
| Passakonnirin, R | 1 |
| Sookpotarom, P | 1 |
| Chittmittrapap, S | 1 |
| Poovorawan, Y | 1 |
| Lachaux, A | 1 |
| Chambon, M | 1 |
| Boillot, O | 1 |
| Le Gall, C | 1 |
| Loras, I | 1 |
| Canterino, I | 1 |
| Pouillaude, JM | 1 |
| Gille, D | 1 |
| David, L | 1 |
| Hermier, M | 1 |
| Higashimoto, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy[NCT03499249] | Phase 2 | 16 participants (Anticipated) | Interventional | 2018-05-18 | Active, not recruiting | ||
| A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants With Biliary Atresia[NCT00294684] | 141 participants (Actual) | Interventional | 2005-11-30 | Completed | |||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Height by Age Z-score over the course of the study (NCT00294684)
Timeframe: HPE to age 24 Months
| Intervention | Z-score (Mean) |
|---|---|
| Corticosteroids | -0.7 |
| Placebo | -0.6 |
(NCT00294684)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Corticosteroids | 5 |
| Placebo | 3 |
(NCT00294684)
Timeframe: 24 Months
| Intervention | participants (Number) |
|---|---|
| Corticosteroids | 1 |
| Placebo | 3 |
(NCT00294684)
Timeframe: Measurements will be made at 3 months after portoenterostomy
| Intervention | mg/dL (Mean) |
|---|---|
| Corticosteroids | 3.5 |
| Placebo | 5.1 |
(NCT00294684)
Timeframe: Measurements will be made at 24 months of age
| Intervention | percentage of participants (Number) |
|---|---|
| Corticosteroids | 58.7 |
| Placebo | 59.4 |
(NCT00294684)
Timeframe: Measurements will be made at 6 months after portoenterostomy
| Intervention | percentage of participants (Number) |
|---|---|
| Corticosteroids | 58.6 |
| Placebo | 48.6 |
(NCT00294684)
Timeframe: 12 Months post HPE
| Intervention | mg/dL (Mean) |
|---|---|
| Corticosteroids | 1.7 |
| Placebo | 3.7 |
(NCT00294684)
Timeframe: At 24 Months of Age
| Intervention | mg/dL (Mean) |
|---|---|
| Corticosteroids | 1.3 |
| Placebo | 1.6 |
weight for age Z-score (in subjects without ascites) over the course of the study (NCT00294684)
Timeframe: HPE until 24 months of age
| Intervention | Z-score (Mean) |
|---|---|
| Corticosteroids | -0.8 |
| Placebo | -0.8 |
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
4 reviews available for prednisolone and Atresia, Biliary
| Article | Year |
|---|---|
Postoperative steroids after Kasai portoenterostomy for biliary atresia: a meta-analysis.
Topics: Biliary Atresia; Cholangitis; Dexamethasone; Glucocorticoids; Humans; Hydrocortisone; Jaundice; Port | 2014 |
Postoperative steroid therapy for biliary atresia: Systematic review and meta-analysis.
Topics: Biliary Atresia; Drainage; Glucocorticoids; Humans; Portoenterostomy, Hepatic; Postoperative Care; P | 2015 |
Steroids after the Kasai procedure for biliary atresia: the effect of age at Kasai portoenterostomy.
Topics: Age Factors; Biliary Atresia; Cholangitis; Glucocorticoids; Humans; Infant; Infant, Newborn; Liver; | 2016 |
Idiopathic thrombocytopenic purpura complicated with biliary atresia: a rare occurrence and literature review.
Topics: Biliary Atresia; Cholangitis; Diagnosis, Differential; Glucocorticoids; Humans; Infant; Liver Transp | 2009 |
5 trials available for prednisolone and Atresia, Biliary
| Article | Year |
|---|---|
Steroids in biliary atresia: single surgeon, single centre, prospective study.
Topics: Biliary Atresia; Bilirubin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose-Response Relatio | 2013 |
Multicenter randomized trial of postoperative corticosteroid therapy for biliary atresia.
Topics: Biliary Atresia; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucocorticoids; Human | 2013 |
Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial.
Topics: Administration, Oral; Adrenal Cortex Hormones; Biliary Atresia; Bilirubin; Double-Blind Method; Drai | 2014 |
Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial.
Topics: Administration, Oral; Adrenal Cortex Hormones; Biliary Atresia; Bilirubin; Double-Blind Method; Drai | 2014 |
Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial.
Topics: Administration, Oral; Adrenal Cortex Hormones; Biliary Atresia; Bilirubin; Double-Blind Method; Drai | 2014 |
Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial.
Topics: Administration, Oral; Adrenal Cortex Hormones; Biliary Atresia; Bilirubin; Double-Blind Method; Drai | 2014 |
Randomized, double-blind, placebo-controlled trial of corticosteroids after Kasai portoenterostomy for biliary atresia.
Topics: Biliary Atresia; Double-Blind Method; Female; Glucocorticoids; Humans; Infant; Liver Transplantation | 2007 |
The improved outlook for biliary atresia with corticosteroid therapy.
Topics: Biliary Atresia; Bilirubin; Cholangitis; Cholestasis; Dose-Response Relationship, Drug; Female; Gluc | 1997 |
16 other studies available for prednisolone and Atresia, Biliary
| Article | Year |
|---|---|
Prednisolone administration monitored by postoperative stool color achieves high jaundice clearance after laparoscopic portoenterostomy for biliary atresia.
Topics: Biliary Atresia; Humans; Infant; Jaundice; Laparoscopy; Portoenterostomy, Hepatic; Prednisolone; Ret | 2023 |
Efficacy of and prognosis after steroid pulse therapy in patients with poor reduction of jaundice after laparoscopic Kasai portoenterostomy.
Topics: Biliary Atresia; Female; Glucocorticoids; Humans; Infant; Infant, Newborn; Jaundice; Laparoscopy; Ma | 2019 |
Pregnancy Outcomes Following Pediatric Liver Transplantation: A Single-Center Experience in Japan.
Topics: Adolescent; Adult; Biliary Atresia; Female; Humans; Immunosuppressive Agents; Japan; Liver Transplan | 2020 |
Vitamin A can ameliorate fibrosis of liver in an established rat model of biliary atresia and Kasai portoenterostomy.
Topics: Animals; Biliary Atresia; Biomarkers; Cholagogues and Choleretics; Disease Models, Animal; Glucocort | 2018 |
Evaluation of a standardized protocol in the use of steroids after Kasai operation.
Topics: Biliary Atresia; Biliary Tract Surgical Procedures; Clinical Protocols; Female; Glucocorticoids; Hum | 2008 |
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Topics: Animals; Biliary Atresia; Biliary Tract Diseases; Cholestasis; Common Bile Duct Diseases; Disease Mo | 2009 |
Evaluating patients' outcome post-Kasai operation: a 19-year experience with modification of the hepatic portoenterostomy and applying a novel steroid therapy regimen.
Topics: Anti-Inflammatory Agents; Biliary Atresia; Combined Modality Therapy; Female; Humans; Hydrocortisone | 2010 |
How valuable is ductal plate malformation as a predictor of clinical course in postoperative biliary atresia patients?
Topics: Bile Ducts; Bile Ducts, Intrahepatic; Biliary Atresia; Bilirubin; Biopsy; Female; Glucocorticoids; H | 2011 |
Liver transplantation in infants younger than 6 months old.
Topics: Age Factors; Antibodies, Monoclonal; Basiliximab; Biliary Atresia; Cyclosporine; Drug Therapy, Combi | 2002 |
C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg.
Topics: Administration, Oral; Antibodies, Monoclonal; Basiliximab; Biliary Atresia; Body Weight; Cyclosporin | 2004 |
Optimum prednisolone usage in patients with biliary atresia postportoenterostomy.
Topics: Anti-Inflammatory Agents; Biliary Atresia; Bilirubin; Cholangitis; Clinical Protocols; Feces; Female | 2005 |
Glucocorticoid receptor alpha expression in the intrahepatic biliary epithelium and adjuvant steroid therapy in infants with biliary atresia.
Topics: Bile Ducts, Intrahepatic; Biliary Atresia; Epithelium; Follow-Up Studies; Glucocorticoids; Humans; I | 2005 |
Cytomegalovirus-associated immune thrombocytopenic purpura after liver transplantation.
Topics: Biliary Atresia; Child, Preschool; Cytomegalovirus Infections; Glucocorticoids; Humans; Liver Transp | 2007 |
The significance of steroid therapy after hepatoportoenterostomy in infants with biliary atresia.
Topics: Biliary Atresia; Female; Glucocorticoids; Humans; Male; Portoenterostomy, Hepatic; Prednisolone; Ret | 2007 |
High-dose steroids do not improve early outcome in biliary atresia.
Topics: Biliary Atresia; Biliary Tract Surgical Procedures; Case-Control Studies; Dose-Response Relationship | 2007 |
Transient hyperphosphatasemia after liver transplantation in infancy.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Biliary Atresia; Bilirubin; | 1996 |